FDA Accepts Javelin Pharmaceuticals’ Dyloject New Drug Application For Formal Review
Toolbox: Crank Down the Pain
Read more on PezCycling News
by Dr. Stephen Cheung, Ph.D. King of Pain At its core, cycling is about pain tolerance. Every single race comes down to a critical point where you either keep up or get left behind.US FDA accepts Javelin Pharma’s Dyloject NDA for formal review
Read more on PharmaBiz
Javelin Pharmaceuticals, Inc, a leading developer and marketer of specialty pharmaceutical products for pain management, announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (US FDA) for its investigational product candidate, Dyloject (diclofenac sodium) Injection, has been accepted for formal review.HSS supports Arthritis Foundation’s educational campaign for osteoarthritis
Read more on News-Medical-Net
Hospital for Special Surgery, (HSS), a world leader in orthopedics and rheumatology, today announced its support of the Arthritis Foundation and Ad Council newly launched campaign, “Moving is the Best Medicine,” to raise awareness of osteoarthritis, increase public health education and support breakthrough research.New research may help adopt acupuncture as a treatment option for NHS patients
Read more on News-Medical-Net
Important new research about the effects of acupuncture on the brain may provide an understanding of the complex mechanisms of acupuncture and could lead to a wider acceptability of the treatment.FDA Accepts Javelin Pharmaceuticals’ Dyloject New Drug Application For Formal Review
Read more on DrugDiscoveryOnline
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, recently announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject (diclofenac sodium) Injection, has been accepted for formal review
Leave a Comment